[144] Mind Medicine (MindMed) Inc. SEC Filing

Rhea-AI Filing Summary

Mind Medicine (MNMD) Form 144 shows an intended sale of 7,704 common shares by a person for whose account the securities were issued, through Morgan Stanley Smith Barney LLC on 09/25/2025 on NASDAQ. The filing reports an aggregate market value of $75,288.88 for the shares and lists 76,087,943 shares outstanding for the issuer. The shares to be sold were acquired the same day, 09/25/2025, as restricted stock vesting under a registered plan and payment is recorded as Not Applicable. The filing also discloses a prior sale by DANIEL ROLLINGS KARLIN of 7,848 shares on 06/25/2025 for gross proceeds of $53,387.59. The notice includes the required signature representation regarding absence of undisclosed material adverse information.

Positive

• Transaction arises from restricted stock vesting, indicating the sale is part of a registered compensation plan
• Broker and exchange specified (Morgan Stanley Smith Barney LLC; NASDAQ), showing a standard execution channel
• Filing includes required signer representation about lack of undisclosed material adverse information

Negative

• Insider sale disclosed—7,704 shares proposed for sale, which may be perceived negatively by some investors
• Prior recent sale by an insider (7,848 shares on 06/25/2025) shows multiple dispositions in the period

Insights

Securities Analyst

TL;DR: Insider intends a routine sale of vested restricted shares via Morgan Stanley, modest in size relative to outstanding shares.

The filing documents a proposed sale of 7,704 common shares acquired on vesting and to be sold on 09/25/2025 through Morgan Stanley Smith Barney on NASDAQ. Relative to the issuer's reported 76,087,943 shares outstanding, the transaction size is immaterial and unlikely to affect market capitalization or liquidity. The disclosure follows Rule 144 format and cites restricted stock vesting under a registered plan, consistent with routine post-vesting dispositions. Investors should note the prior disclosed sale of 7,848 shares by Daniel Rollings Karlin on 06/25/2025 for $53,387.59 as context for recent insider activity.

Compliance / Risk Analyst

TL;DR: Filing appears procedural and compliant, showing planned disposition of vested awards with required certifications.

The Form 144 provides the broker, share count, aggregate value, acquisition method, and sale date, and includes the signers representation about lack of undisclosed material adverse information. The acquisition is explicitly listed as restricted stock vesting under a registered plan, and payment is noted as not applicable, indicating no non-cash consideration. From a compliance perspective the notice contains the customary elements needed for Rule 144 transactions. There is no indication in the filing of atypical payment arrangements, pledging, or aggregation issues beyond a recent separate sale disclosed in the form.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	7704	75288.88	76087943	09/25/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/25/2025	Restricted stock vesting under a registered plan	Issuer			7704	09/25/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
DANIEL ROLLINGS KARLIN One World Trade Center, Suite 8500 New York NY 10007	Common	06/25/2025	7848	53387.59

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the MNMD Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 7,704 common shares through Morgan Stanley Smith Barney LLC on 09/25/2025 on NASDAQ with an aggregate market value of $75,288.88.

How were the MNMD shares acquired that are to be sold?

The shares were acquired on 09/25/2025 as restricted stock vesting under a registered plan.

Does the filing show any recent insider sales for MNMD?

Yes. The filing reports that DANIEL ROLLINGS KARLIN sold 7,848 shares on 06/25/2025 for gross proceeds of $53,387.59.

How many MNMD shares are outstanding according to the filing?

The filing lists 76,087,943 shares outstanding for the issuer.

Is there any special payment arrangement noted for the MNMD shares?

Payment is listed as Not Applicable, and no non-cash consideration or installment arrangements are described.